Form 4 for CRVS Corvus Pharmaceuticals, Inc.
Accepted 2026-06-15 17:12:29 ET · period of report 2026-06-11 · accession 0001610717-26-000223 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-15 17:12 | 2026-06-11 | CRVS | Moore David Scott | Dir | P - Purchase | $11.53 | +21.7K | 21.7K | New | +$250.2K |
| D | 2026-06-15 17:12 | 2026-06-11 | CRVS | Moore David Scott | Dir | A - Grant | $0.00 | +15.0K | 15.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-11 | P | A | 21,700 | $11.53 | 21,700 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-06-11 | A | A | 15,000 | $0.00 | 15,000 | D | $11.60 · — to 2036-06-11 | 15,000 Common Stock | (F1) The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |